

Name of Journal: *World Journal of Stem Cells*

Manuscript NO: 64490

Manuscript Type: REVIEW

Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells

Sukowati CHC *et al.* Anti PD-1/PD-L1 and cellular heterogeneity in HCC

Caecilia H C Sukowati, Korri Elvanita El-Khobar, Claudio Tiribelli

Match Overview

1	Internet 125 words www.ncbi.nlm.nih.gov	1%
2	Internet 61 words crawled on 07-Nov-2020 www.karger.com	1%
3	Internet 61 words crawled on 14-Jun-2020 www.frontiersin.org	1%
4	Internet 53 words crawled on 29-Sep-2020 www.hindawi.com	<1%
5	Internet 52 words crawled on 26-Nov-2015 cancerres.aacrjournals.org	<1%
6	Internet 52 words crawled on 18-May-2016 www.nature.com	<1%
7	Crossref 51 words Sheema Almozyan, Dilek Colak, Fatmah Mansour, Ayodele Alaiya et al. "PD-L1 promotes OCT4 and Nanog expression"	<1%
8	Internet 51 words crawled on 15-Jul-2020 docplayer.net	<1%
9	Internet 47 words crawled on 28-Dec-2019 academic.oup.com	<1%
10	Crossref 45 words Huy Q Do, An B Luong, Deborah Bonazza, Cristina Bottin et al. "Differential capacity of CD90+ cells in autophagy ..."	<1%

Immunotherapy against programmed death-1/programmed death l



ALL

IMAGES

VIDEOS

57,600 Results

Any time ▾

Programmed Death-Ligand 1 - an overview | ScienceDirect ...

<https://www.sciencedirect.com/topics/chemistry/programmed-death-ligand-1>

The **programmed cell death 1 (PD-1)** receptor is another inhibitory receptor expressed by **T cells** whose primary **ligand**, **programmed cell death 1 ligand (PD-L1; CD274)**, is frequently expressed within the tumor microenvironment. PD-1 signaling in tumors is required for both suppressing effector T cells and maintaining tumor regulatory T cells (Tregs).

Programmed cell death-1/Programmed cell death ligand ...

<https://www.sciencedirect.com/science/article/pii/S2468294216301265>

Jan 01, 2017 · The **PD-1 (programmed cell death-1)** receptor is a transmembrane inhibitory protein and member of the CD28 receptor family which is only expressed on activated T-cells, B-cells and monocytes. [34] It shares 21% to 33% homology with CTLA-4/CD28/inducible co-stimulator (ICOS).

Cited by: 6

Author: Foluso Ogunleye, LeAnn Blankenship, Va...

Publish Year: 2017

Programmed cell death-ligand 1 expression in ...

<https://onlinelibrary.wiley.com/doi/10.1111/jgh.15475>

Programmed cell death-ligand 1 (PD-L1) immunohistochemistry score has been approved as the predictive biomarker for anti-PD1/PD-L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive in **hepatocellular carcinoma**, ongoing study of anti-PD1/PD-L1 therapy showed promising results.

Author: Haibo Mou, Qiu-an Yang, Lanfang Yu, ... Publish Year: 2021

Molecular Pathways: Next-Generation Immunotherapy ...

<https://www.researchgate.net/publication/232535703...>

Immunotherapy is a very promising therapy for lung cancer; however, cancer cells can express membrane proteins such as **programmed death-ligand 1** ...

Cancer immunotherapy: Macs in the middle: Immunity

[https://www.cell.com/immunity/fulltext/S1074-7613\(21\)00078-9](https://www.cell.com/immunity/fulltext/S1074-7613(21)00078-9) ▾

Immune checkpoint blockade (ICB) using monoclonal antibodies against cytotoxic T-lymphocyte antigen-4 (CTLA-4), **programmed cell death 1 (PD-1)**, and **PD-ligand 1 (PD-L1)** that invigorate tumor-specific CD8 + T cells have revolutionized the treatment of many cancers. However, ICB efficacy in responsive cancer types is variable, and most patients with common cancers of the gastrointestinal tract

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

55,000 Results

Any time ▾

Open links in new tab



[Frontiers | The Efficacy and Safety of Programmed Death-1 ...](#)

<https://www.frontiersin.org/articles/10.3389/fonc.2021.626984>

Mar 23, 2021 · Keywords: **hepatocellular carcinoma**, immune checkpoint inhibitors, PD-1/PD-L1 inhibitors, **immunotherapy**, meta-analysis. Citation: He S, Jiang W, Fan K and Wang X (2021) The Efficacy and Safety of **Programmed Death-1** and **Programmed Death Ligand 1** Inhibitors for the Treatment of **Hepatocellular Carcinoma**: A Systematic Review and Meta-Analysis. Front.

Author: Shukang He, Weichao Jiang, Kai Fan, Xi... **Publish Year:** 2021

[Programmed Death-Ligand 1 - an overview | ScienceDirect Topics](#)

<https://www.sciencedirect.com/topics/chemistry/programmed-death-ligand-1>

The **programmed cell death 1** (PD-1) receptor is another inhibitory receptor expressed by T **cells** whose primary **ligand**, **programmed cell death 1 ligand** (PD-L1; CD274), is frequently expressed within the tumor microenvironment. PD-1 signaling in tumors is required for both suppressing effector T **cells** and maintaining tumor regulatory T **cells** (Tregs).

[Programmed cell death-1/Programmed cell death ligand-1\(PD ...](#)

<https://www.sciencedirect.com/science/article/pii/S2468294216301265>

Jan 01, 2017 · The PD-1 (**programmed cell death-1**) receptor is a transmembrane inhibitory protein and member of the CD28 receptor family which is only expressed on activated T-**cells**, B-**cells** and monocytes. [34] It shares 21% to 33% homology with CTLA-4/CD28/inducible co-stimulator (ICOS).

Cited by: 6 **Author:** Foluso Ogunleye, LeAnn Blankenship, Vane...

Publish Year: 2017

[Programmed cell death-ligand 1 expression in ...](#)

<https://onlinelibrary.wiley.com/doi/10.1111/jgh.15475>

Programmed cell death-ligand 1 (PD-L1) immunohistochemistry score has been approved as the predictive biomarker for anti-PD1/PD-L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive in **hepatocellular carcinoma**, ongoing study of anti-PD1/PD-L1 therapy showed promising results.

Author: Haibo Mou, Qiu-an Yang, Lanfang Yu, Ti... **Publish Year:** 2021

[Molecular Pathways: Next-Generation Immunotherapy ...](#)

<https://www.researchgate.net/publication/232535703...>